A nightly pill for obstructive sleep apnea could soon offer millions of patients an alternative to bulky breathing machines, following positive results from a large late-stage clinical trial. The experimental drug, known as AD109, reduced breathing interruptions by nearly 44 percent over six months, and almost 18 percent of participants experienced no further apnea episodes by the end of the study. The US Food and Drug Administration has fast-tracked the review, with a decision expected in 2027.
Obstructive sleep apnea affects nearly one billion people worldwide. The condition causes repeated airway collapse during sleep, leading to gasping, snoring, and daytime exhaustion. Over time, it can damage the heart, brain, and blood vessels. The standard treatment is a CPAP machine, which keeps the airway open with pressurized air. While effective, many patients find the mask and device uncomfortable or cumbersome, and a large number stop using it. “An oral pill that targets the underlying neuromuscular drivers of airway collapse during sleep could help address this gap,” said Dr. Patrick John Strollo, a sleep medicine physician at the University of Pittsburgh Medical Center.
The phase 3 trial enrolled 646 patients from the US and Canada who had mild to severe sleep apnea but could not tolerate or refused CPAP. Participants took either AD109 or a placebo nightly for 26 weeks. The drug combines two well-understood compounds: aroxybutynin, which calms the parasympathetic nervous system, and atomoxetine, an ADHD medication. Together, they prevent the brain from relaxing the upper airway muscles during sleep. By week 26, nearly 42 percent of those on the drug moved to a less severe category of sleep apnea. Side effects were mild and included dry mouth, nausea, and insomnia, which researchers expected given the drug’s known components.
Beyond the CPAP Machine
AD109 is not the only alternative in development. Other recent trials have shown promise for repurposed epilepsy drugs and GLP-1 medications for patients whose apnea is linked to obesity. Experimental approaches include implanting electrodes in the tongue and even using muscle-toning exercises with a conch shell. But a convenient nightly pill could offer the widest appeal. “These results provide encouraging evidence that targeting neuromuscular dysfunction can translate into meaningful clinical outcomes,” Dr. Strollo said. If approved, AD109 would give millions of patients a new, comfortable option to treat a condition that has long lacked pharmaceutical solutions.